Verge Genomics

📍 South San Francisco, United States🗓 Founded 2015👥 57 employees💰 Last funded Nov 2021
Biotechnology Research🌐 vergegenomics.com
Website LinkedIn
Verge Genomics is a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data. Verge is focused on developing therapeutics for complex diseases with high unmet need, using human genomics from patient disease tissues and machine learning. Verge has created a proprietary all-in-human CONVERGE® platform, featuring one of the field’s largest and most comprehensive databases of multi-omic patient data. The company is led by experienced computational biologists and drug developers who are successfully advancing clinical and preclinical therapeutic programs in various diseases, including ALS and Parkinson’s disease. Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
7
Total investors
1
Early stage
5
Mid stage
1
Late stage
2015
Founded

Investors

7 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
7
Investor activity2015–2021 · investors recorded per year
20151201832020220211
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Verge Genomics?
Verge Genomics has 7 investors on record on gritt.io, including 1 early-stage backers, 5 mid-stage and 1 late-stage investors.
When did Verge Genomics last raise funding?
The most recent investment in Verge Genomics recorded on gritt.io was in November 2021.
When was Verge Genomics founded?
Verge Genomics was founded in 2015.
What industry is Verge Genomics in?
Verge Genomics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Verge Genomics based?
Verge Genomics is headquartered in South San Francisco, United States.